Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study

被引：0

作者：

Saunders, Ashley C. ^{[1
]}

Singh, Tavneet ^{[2
]}

Lee, Abraham ^{[2
]}

Farazi, Thalia ^{[3
]}

Fasan, Omotayo ^{[1
]}

Mirza, Sana ^{[2
]}

McGarvey, November ^{[2
]}

机构：

[1] Bristol Myers Squibb, Princeton, NJ USA

[2] BluePath Solut, Los Angeles, CA USA

[3] Bristol Myers Squibb, San Francisco, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178771

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 24 条

[1] Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study
Awan, Farrukh T.
McGarvey, November
Lee, Abraham
Imanak, Ken
Tiwana, Simran K.
Garrison, Sean
Priyadarshini, Masoom
BLOOD, 2023, 142
[2] TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)
Nastoupil, Loretta J.
Dahiya, Saurabh
Palomba, M. Lia
Martin Garcia-Sancho, Alejandro
Reguera Ortega, Juan Luis
Kuruvilla, John
Jager, Ulrich
Cartron, Guillaume
Izutsu, Koji Izutsu
Dreyling, Martin
Kahl, Brad
Ghesquieres, Herve
Ardeshna, Kirit
Goto, Hideki
Barbui, Anna Maria
Abramson, Jeremy S.
Borchmann, Peter
Fleury, Isabelle
Mielke, Stephan
Farazi, Thalia
Fasan, Omotayo
Lymp, James
Vedal, Min
Nishii, Rina
Avilion, Ariel
Papuga, Jessica
Morschhauser, Frank
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S447 - S448
[3] Estimation of Postinfusion Resource Use and Total Costs of Care for Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study
Saunders, Ashley C.
Singh, Tavneet
Lee, Abraham
Farazi, Thalia
Fasan, Omotayo
Mirza, Sana
McGarvey, November
BLOOD, 2023, 142
[4] TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
Borchmann, Peter
Morschhauser, Franck
Dahiya, Saurabh
Palomba, M. Lia
Garcia-Sancho, Alejandro Martin
Reguera Ortega, Juan Luis
Kuruvilla, John
Jaeger, Ulrich
Cartron, Guillaume
Izutsu, Koji
Dreyling, Martin
Kahl, Brad
Ghesquieres, Herve
Ardeshna, Kirit
Goto, Hideki
Barbui, Anna Maria
Abramson, Jeremy S.
Fleury, Isabelle
Mielke, Stephan
Farazi, Thalia
Fasan, Omotayo
Lymp, James
Vedal, Min
Nishii, Rina
Avilion, Ariel
Papuga, Jessica
Nastoupil, Loretta J.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 143
[5] Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R/R follicular lymphoma (FL)
Luis Reguera, Juan
Garcia-Sancho, Alejandro Martin
Kuruvilla, John
Izutsu, Koji
Maria Barbui, Anna
Peter, Borchmann
Mielke, Stephan
Lia Palomba, Maria
Cartron, Guillaume
Ghesquieres, Herve
Goto, Hideki
Varadarajan, Indumathy
Farazi, Thalia
Hui Kao, Grace Shih
Vedal, Min
Nishii, Rina
Papuga, Jessica
Morschhauser, Franck
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Abramson, Jeremy S.
Siddiqi, Tanya
Gordon, Leo, I
Lunning, Matthew Alexander
Wang, Michael
Arnason, Jon E.
Mehta, Amitkumar N.
Purev, Enkhee
Maloney, David G.
Andreadis, Charalambos
Sehgal, Alison R.
Solomon, Scott R.
Ghosh, Nilanjan
Albertson, Tina M.
Garcia, Jacob
Kostic, Ana
Li, Daniel
Kim, Yeonhee
Palomba, Maria Lia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)
Cartron, Gillaume
Garcia-Sancho, Alejandro Martin
Reguera, Juan Luis
Dahiya, Saurabh
Guo, Shien
Shi, Ling
Eliason, Laurie
Kumar, Jinender
Farazi, Thalia
Fasan, Omotayo
Izutsu, Koji
BLOOD, 2023, 142
[8] Post-Infusion Monitoring Costs and Health Care Resource Utilization (HCRU) by Site of Care (SOC) in Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 (TRANSCEND) Study
McGarvey, November
Lee, Abraham
Imanak, Ken
Tiwana, Simran K.
Garrison, Sean
Priyadarshini, Masoom
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S516 - S517
[9] Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
Dahiya, Saurabh
Hirayama, Alexandre V.
Schuster, Stephen J.
Reguera Ortega, Juan Luis
Morschhauser, Franck
Garcia-Sancho, Alejandro Martin
Kuruvilla, John
Izutsu, Koji
Maria Barbui, Anna
Borchmann, Peter
Mielke, Stephan
Cartron, Guillaume
Ghesquieres, Herve
Goto, Hideki
Varadarajan, Indumathy
Kamdar, Manali
Isufi, Iris
Farazi, Thalia
Kao, Grace Shih Hui
Vedal, Min
Bhatnagar, Rashmi
Nishii, Rina
Papuga, Jessica
Lia Palomba, M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S462 - S463
[10] Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017) in TRANSCEND NHL 001.
Abramson, Jeremy S.
Siddiqi, Tanya
Garcia, Jacob
Dehner, Christine
Nguyen, Andy
Snyder, Sophie
Gitlin, Matthew
Chung, Karen C.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 →